Fundraising FoxBTB Therapeutics, Inc.
Escondido, US · Founded 2024 · Delaware corporation · 1 known investors
Find your way into BTB Therapeutics, Inc.
Sign up to see every warm intro you have to BTB Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BTB Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.
Founders & leadership
BTB Therapeutics, Inc. was founded in 2024 by Masatoshi Hagiwara.
MH
TK
Takashi KiyoizumiChief Executive OfficerTakashi Kiyoizumi holds an MD, PhD, and MBA from MIT Sloan. He has served as CEO of multiple pharmaceutical startups and held board positions in life science companies, with experience in capital raising and strategic licensing agreements.
Investors · 1
Reported raises · per SEC filings
Form D private placements$12.2M disclosed across 2 rounds · 2025
▶$8.9MraisedAug 2026 · 4 investors · PharmaceuticalsRule 506(b)
▶$8.9MraisedAug 2026 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Takashi KiyoizumiExecutive Officer, Director
- Nobuhiro YagiDirector
- Masatoshi HagiwaraDirector
- David SnyderDirector
- Sidney YeeDirector
- Offering amount
- $10.4M
- Amount sold
- $8.9M
- Proceeds to insiders
- $250K
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$3.3MraisedFeb 2025 · 10 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedFeb 2025 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Takashi KiyoizumiExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through BTB Therapeutics, Inc. went on to found or lead other companies.
Related companies · 8
Northwest BiotherapeuticsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.
Crossbow TherapeuticsCrossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
Shinobi Therapeutics Inc.Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.
Krystal BiotechKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
C4 TherapeuticsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Bolt BiotherapeuticsBolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer. The company focuses on cancer immunotherapeutics and myeloid biology to address unmet patient needs.
ObsidiantxObsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
Companies working in the same space as BTB Therapeutics, Inc..
Frequently asked questions
- What does BTB Therapeutics, Inc. do?
- BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.
- Who founded BTB Therapeutics, Inc.?
- BTB Therapeutics, Inc. was founded by Masatoshi Hagiwara in 2024.
- Who are BTB Therapeutics, Inc.'s investors?
- BTB Therapeutics, Inc.'s investors include Kyoto University Innovation Capital.
- How much funding has BTB Therapeutics, Inc. raised?
- BTB Therapeutics, Inc. has disclosed $12.2M raised across 2 rounds.
- Where is BTB Therapeutics, Inc. headquartered?
- BTB Therapeutics, Inc. is headquartered in Escondido, US.